TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8256468
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (600 mg of D‐alpha tocopherol per day, 200 micrograms of selenium, and 12 mg of zinc)
Study: 23514246
Drug: Primary radiotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary radiotherapy (RT) ± chemotherapy
Study: 16963850
Drug: Anecortave acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anecortave acetate 30 mg
Study: 16963850
Drug: Anecortave acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anecortave acetate 3 mg
Study: 15072030
Drug: Levofloxacin 300
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 300 mg orally once daily (LEV group)
Study: 15072030
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid 625 mg three times a day (COA group)
Study: 9626225
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m2 intravenously (i.v.) over 30 minutes daily for 5 days repeated every 21 days (arm A)
Study: 9626225
Drug: Topotecan 1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.75 mg/m2 as a 24-hour infusion once a week for 4 weeks repeated every 6 weeks (arm B)
Study: 14980942
Drug: Combined spinal-epidural
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal-epidural anesthesia (CSE) with intrathecal hyperbaric 0.5% bupivacaine 5 mg and fentanyl 10 microg, followed by 0.9% saline 6.0 mL through the epidural catheter 5 min thereafter
Study: 14980942
Drug: Single-shot spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot spinal anesthesia with hyperbaric 0.5% bupivacaine 9 mg and fentanyl 10 microg
Study: 9619732
Drug: High-dose ara-C/daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ara-C/daunorubicin (HDara-C/DNR) after idarubicin induction
Study: 9619732
Drug: High-dose ara-C/daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ara-C/daunorubicin (HDara-C/DNR) after daunorubicin induction
Study: 7633693
Drug: Nasal immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal immunotherapy (LNIT) with Parietaria
Study: 2675377
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg x 2/day for two weeks, then 10 mg x 2/day for two months)
Study: 2675377
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg/day for two months)
Study: 359017
Drug: Nordiazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordiazepam (5 mg)
Study: 42628
Drug: Nordiazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordiazepam (10 mg)
Study: 359017
Drug: Oxazepam (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (45 mg)
Study: 359017
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg) morning ingestion
Study: 359017
Drug: Temazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (20 mg) morning ingestion
Study: 359017
Drug: Oxazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (30 mg) morning ingestion
Study: 359017
Drug: Nordiazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordiazepam (10 mg) morning ingestion
Study: 359017
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg) choice response time test
Study: 359017
Drug: Temazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (20 mg) choice response time test
Study: 25833972
Drug: WinFood-Lite (WF-L)
Normalized name: Lite 'N Foamy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WinFood-Lite (WF-L)
Study: 19288533
Drug: Castor oil
Normalized name: Castor Oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Castor oil capsule 0.9 mL, thrice daily for 4 weeks
Study: 19288533
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium capsule 50 mg, thrice daily for 4 weeks
Study: 14748914
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor antagonism
Study: 11395029
Drug: Fortified fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified fat spread (25 g/day providing 2.5 g of plant sterols)
Study: 9232297
Drug: PCEA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA using meperidine with background infusion (group Pi)
Study: 9232297
Drug: PCEA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA using meperidine without background infusion (group Po)
Study: 8125422
Drug: Captopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (ACE inhibitor), started after the first day but within 72 hours of onset of chest pain
Study: 7836197
Drug: Aminophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (5 mg/kg)
Study: 22768459
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% dextrose water for injection, 5 cc/kg)
Study: 16510384
Drug: Topical Symphytum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Symphytum product Traumaplant (10% active ingredient)
Study: 16510384
Drug: 1% reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% reference product (2.5 g of fresh comfrey herb in 100 g of cream)
Study: 8848206
Drug: Bromocriptine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (up to 60 mg/d)
Study: 2081142
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 120 mg (V120 SR) given twice daily (bid)
Study: 2081142
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 240 mg (V240 SR) given once daily (od)
Study: 35414
Drug: Clonidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2 X 0.025 mg/24 hours - 0.075 mg/24 hours, increased if necessary at intervals of two weeks)
Study: 24092827
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.05 mg/d)
Study: 11096165
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg)
Study: 21440672
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bisacodyl once daily for 4 weeks
Study: 19146605
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Arctium lappa fruit extract-containing formulation for 12 weeks
Study: 19146605
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Arctium lappa fruit extract-containing formulation for 4 weeks
Study: 9167505
Drug: Sertindole 20
Normalized name: sertindole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole 20 mg/day
Study: 8935813
Drug: Sertindole (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (various doses)
Study: 3159639
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine alone (Group I)
Study: 3159639
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine + HBIG at birth (Group II)
Study: 3159639
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine + HBIG at birth and again at one month (Group III)
Study: 22734376
Drug: Acupuncture-rehabilitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-rehabilitation group (routine rehabilitation therapy combined with electroacupuncture therapy)
Study: 12058428
Drug: Amrinone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (5 mcg.kg‐1.min‐1) administered after coronary artery anastomosis (A 1 group: 11 cases)
Study: 12058428
Drug: Amrinone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (5 mcg.kg‐1.min‐1) administered after induction of anesthesia (A 2 group: 13 cases)
Study: 6173522
Drug: Captopril 150
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril 150 mg/day
Study: 8603632
Drug: Felbamate (FBM)
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate (FBM) at doses of 1,200, 2,400, 3,000, or 3,600 mg/day (n = 2-4 per group)
Study: 1936112
Drug: 54Fe-labelled iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54Fe-labelled iron preparation (150 mg Fe2+ daily)
Study: 1936112
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available iron preparation (160 mg Fe2+ daily)
Study: 7011299
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.3 mg
Study: 7011299
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.3 mg + ephedrine hydrochloride 25 mg
Study: 19565729
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (Flunarizine tablets)
Study: 17419283
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg clarithromycin (C250 group)
Study: 17419283
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg clarithromycin and 500 mg vitamin C (V-C250 group)
Study: 17419283
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg clarithromycin (C500 group)
Study: 11157010
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks (arm A)
Study: 11157010
Drug: Mitoxantrone 23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 23 mg/m² plus cyclophosphamide 600 mg/m² with filgrastim 5 µg/kg/d from days 2 to 15 every 3 weeks (arm B)
Study: 11157010
Drug: Mitoxantrone 23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 23 mg/m² plus cyclophosphamide with filgrastim (arm B)
Study: 11157010
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² (arm A)
Study: 26508701
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (0.45 mg/day) with progesterone (200 mg/day for 12 days each month)
Study: 26508701
Drug: Transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐estradiol (50 μg/day) with progesterone (200 mg/day for 12 days each month)
Study: 21458845
Drug: Memantine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 20 mg/d
Study: 9223203
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.25% bupivacaine (group C, n = 10)
Study: 9223203
Drug: Intermittent hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent hourly bolus of 0.25% bupivacaine (group B, n = 10)
Study: 8124207
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg bd)
Study: 3303813
Drug: Low-dose prostaglandin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prostaglandin F2 alpha (PGF2 alpha, up to 6.0 micrograms/min)
Study: 2809851
Drug: Coloured luting
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coloured luting agents
Study: 27028190
Drug: tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.2 mg plus solifenacin 5 mg (Group II)
Study: 27028190
Drug: tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.2 mg plus solifenacin 10 mg (Group III)
Study: 27028190
Drug: tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.2 mg (Group I)
Study: 19221919
Drug: Therapist-guided web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided web-based cognitive behavioural treatment (web-CBT)
Study: 16916668
Drug: Midazolam (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.4 mg.kg(‐1).h(‐1))
Study: 7936339
Drug: Dopexamine infusion
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine infusion at a dose of 1 microgram/kg/m during aortic cross-clamping and 0.5 micrograms/kg/m from declamping to the end of surgery
Study: 7936339
Drug: No dopexamine
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dopexamine infusion (Control Group I)
Study: 29998356
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy applied on the right side
Study: 29998356
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy applied on the left side
Study: 22372531
Drug: Prasugrel (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (30 mg)
Study: 21171738
Drug: Self-Motivational (SM)
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Motivational (SM) orientation + Parent-Child Interaction Therapy (PCIT)
Study: 18386606
Drug: Trimebutine 100
Normalized name: trimebutine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine 100 mg t.i.d.
Study: 12492804
Drug: Clonidine 4
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 4 micro g kg‐1 in apple juice 0.2 ml kg‐1
Study: 12492804
Drug: Apple juice
Normalized name: apple juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple juice 0.2 ml kg‐1 (Control)
Study: 2967184
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Bisoprolol 5 mg, Bisoprolol 10 mg, Atenolol 100 mg)
Study: 27410392
Drug: Individualised nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised nutritional care by a dietitian, including prescription of wound healing supplements
Study: 19800680
Drug: T suis
Approvals — FDA: no, EMA: no, PMDA: no
Description: T suis ova (2500 live ova, 8 doses, 21-day interval)
Study: 12172716
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: 50-ml mixture of 20 ml 0.5% bupivacaine hydrochloride, 10 ml 2% lidocaine hydrochloride, and 20 ml 0.9% sodium chloride; knee joint injected with 40 ml of the mixture; portal sites injected with 10 ml of the mixture.
Study: 12172716
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: Same mixture as Group I with 250 micro g epinephrine added; knee joint injected with 40 ml of the mixture; portal sites injected with 10 ml of the mixture.
Study: 12172716
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: Same mixture as Group I with 50 micro g epinephrine added to 10 ml of the mixture for portal site injections; knee joint injected with 40 ml of the mixture.
Study: 8578174
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of recombinant interferon-alpha-2b (3 MIU, 3/7 days)
Study: 8578174
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of recombinant interferon-alpha-2b (1 MIU, 3/7 days)
Study: 347229
Drug: Sustained-release procainamide
Normalized name: procainamide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release procainamide (PAD)
Study: 27092789
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg once a day for 12 weeks
Study: 22288493
Drug: Daily reports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily reports tapping experienced or experienced and witnessed negative events
Study: 22288493
Drug: No daily
Normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No daily reports
Study: 11753127
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive therapies using thermal energy to ablate prostatic tissue
Study: 9990599
Drug: High impedance
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High impedance steroid‐eluting pacing leads (Medtronic model 5534 and 5034)
Study: 9990599
Drug: Standard steroid‐eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard steroid‐eluting pacing leads (Medtronic model 5524 and 5024)
Study: 9990599
Drug: High impedance
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High impedance steroid‐eluting pacing leads (Medtronic model 5534)
Study: 9990599
Drug: Standard steroid‐eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard steroid‐eluting pacing leads (Medtronic model 5524)
Study: 9990599
Drug: High impedance
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High impedance steroid‐eluting pacing leads (Medtronic model 5034)
Study: 9990599
Drug: Standard steroid‐eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard steroid‐eluting pacing leads (Medtronic model 5024)
Study: 7579565
Drug: Cisplatin 20
Normalized name: CISPLATIN 200MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 20 mg/m2 in 15 min i.v. infusion followed by FA 500 mg/m2 in 1 h i.v. infusion, with 5-FU 500 mg/m2 i.v. bolus administered in the middle, repeated weekly for 4 weeks followed by a 2 week rest, for a maximum of six cycles.
Study: 1377769
Drug: Synthetic substance
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic substance P (SP) at doses of 0.5, 1.0, or 1.5 pmol/kg‐1/min‐1 for 60 minutes
Study: 6373161
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 to 150 mg)
Study: 6373161
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 to 30 mg)
Study: 24590257
Drug: Long-term antidepressant
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antidepressant medication
Study: 24590257
Drug: Continuing antipsychotic
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing antipsychotic medication
Study: 24590257
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further antidepressant treatment
Study: 19282169
Drug: Sunitinib 37.5mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5mg/day (morning dosing)
Study: 19282169
Drug: Sunitinib 37.5mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5mg/day (evening dosing)
Study: 19282169
Drug: Sunitinib 37.5mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5mg/day (both morning and evening dosing)
Study: 15281507
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (droperidol and ondansetron with isoflurane and nitrous oxide)
Study: 7406249
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 2 mg/kg/day
Study: 8598594
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (alteplase)
Study: 17263767
Drug: Alcohol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.4 g/kg) during hypoglycaemia (2.8 mmol/l for 65 min)
Study: 17263767
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during hypoglycaemia (2.8 mmol/l for 65 min)
Study: 17263767
Drug: Alcohol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.4 g/kg) during euglycaemia
Study: 28139557
Drug: Ranolazine 500
Normalized name: ranolazine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 500 mg twice daily
Study: 15093870
Drug: Ranolazine 1500
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 1500 mg twice daily
Study: 15093870
Drug: Ranolazine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (all doses)
Study: 254058
Drug: Dorsogluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsogluteal injection with femur internally rotated (narcotic medication)
Study: 254058
Drug: Dorsogluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsogluteal injection with femur externally rotated (narcotic medication)
Study: 254058
Drug: Dorsogluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsogluteal injection with femur internally rotated (diazepam)
Study: 254058
Drug: Dorsogluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsogluteal injection with femur externally rotated (diazepam)
Study: 254058
Drug: Dorsogluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsogluteal injection (diazepam)
Study: 31403814
Drug: Body Project
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Project Treatment (BPT)
Study: 25677380
Drug: Levamisole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 2.5 mg kg(‐1) orally once every other day
Study: 15129980
Drug: Vaginal clotrimazole
Normalized name: clotrimazole Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal clotrimazole cream
Study: 15129980
Drug: Test gel
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test gel product
Study: 11556579
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of albendazole 400 mg (A1, n=34)
Study: 11556579
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of albendazole 400 mg daily (A3, n=34)
Study: 11556579
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of albendazole 400 mg daily (A5, n=35)
Study: 11556579
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of albendazole 400 mg plus praziquantel 40 mg/kg (AIP1, n=34)